Emerging investigations on retatruded, a dual agonist for glucagon-like peptide-1 and gastric inhibitory polypeptide, demonstrate significant findings in treating weight gain and type 2 glucose intolerance. Preliminary information from clinical assessments point to considerable reductions in body